Drugs by condition
Drugs approved for obesity and weight management
Last checked: Nov 19, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
15
Still marketed, NDA or BLA
Drug classes
5
Novel drugs
7
New molecular entities and new biologics
In development
40+
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for obesity and weight management.
- Foundayo (Orforglipron Calcium) · Eli Lilly and CO NovelApr 1, 2026
- Arynta (Lisdexamfetamine Dimesylate) · Azurity Jun 16, 2025
- Zepbound (Tirzepatide) · Eli Lilly and CO NovelBreakthrough therapyPriority reviewNov 8, 2023
- Wegovy (Semaglutide) · Novo NovelBreakthrough therapyAccelerated approvalPriority reviewJun 4, 2021
- Imcivree (Setmelanotide Acetate) · Rhythm NovelBreakthrough therapyPriority reviewOrphanNov 25, 2020
All approved drugs for obesity and weight management, by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 68 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
Glucose-dependent Insulinotropic Polypeptide Receptor Agonist (1)
- Zepbound Tirzepatide · Eli Lilly and CO · 2023
Melanocortin 4 Receptor Agonist (1)
- Imcivree Setmelanotide Acetate · Rhythm · 2020
GLP-1 Receptor Agonist (1)
- Saxenda Liraglutide · Novo · 2014
Intestinal Lipase Inhibitor (1)
- Xenical Orlistat · Cheplapharm · 1999
Class not listed in FDA's data (11)
- Foundayo Orforglipron Calcium · Eli Lilly and CO · 2026
- Wegovy Semaglutide · Novo · 2021
- Vyvanse Lisdexamfetamine Dimesylate · Takeda Pharms USA · 2007
- Arynta Lisdexamfetamine Dimesylate · Azurity · 2025
- Vyvanse Lisdexamfetamine Dimesylate · Takeda Pharms USA · 2017
- Contrave Bupropion Hydrochloride, Naltrexone Hydrochloride · Azurity · 2014
- Qsymia Phentermine Hydrochloride, Topiramate · Vivus LLC · 2012
- Phendimetrazine Tartrate Phendimetrazine Tartrate · Acertis Pharms · 1979
- Pregnyl Gonadotropin, Chorionic · Organon USA LLC · 1976
- Chorionic Gonadotropin Gonadotropin, Chorionic · Ferring · 1974
- Chorionic Gonadotropin Gonadotropin, Chorionic · Fresenius Kabi USA · 1973
Drugs in development for obesity and weight management
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- BerobenatidePF-08653944, MET097Phase 319 trials
Pfizer · Obesity, Overweight and/or Obesity, Overweight
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- Maridebart cafraglutideAMG 133Phase 314 trials
Amgen · Obesity, Overweight, Obstructive Sleep Apnea
- EloralintideLY3841136Phase 313 trials
Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2
- HRS9531Phase 313 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- NNC0487-0111Phase 312 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- BofanglutideGZR18, BofanglutidaPhase 311 trials
Gan & Lee Pharmaceuticals. · Type 2 Diabetes Mellitus (T2DM), Obstructive Sleep Apnea (OSA), Obesity/Overweight in Adult
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
- UBT251Phase 310 trials
The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2
- ElecoglipronPhase 39 trials
AstraZeneca · Type 2 Diabetes Mellitus, Obesity, Overweight
- LenbelintideAZD6234Phase 39 trials
AstraZeneca · Obesity or Overweight, Obesity, Overweight
- matched to NNC0487-0111Phase 39 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- ZenagamtidePhase 39 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- EcnoglutideXW003, VRB-101Phase 38 trials
Hangzhou Sciwind Biosciences Co., Ltd. · Obesity, Weight Management, OSA - Obstructive Sleep Apnea
- IBI362Phase 38 trials
Innovent Biologics (Suzhou) Co. Ltd. · Obesity, Overweight, Sleep Apnea
- OlatorepatideHS-20094Phase 38 trials
Jiangsu Hansoh Pharmaceutical Co., Ltd. · Type 2 Diabetes, Overweight or Obesity, Overweight or Obesity Without Diabetes
- AleniglipronPhase 36 trials
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics · Obesity, Overweight, Chronic Weight Management
- CagriSemaCagrilintide B and Semaglutide IPhase 36 trials
Novo Nordisk · Obesity, Diabetes Mellitus, Type 2, Hypertension
- LUM-201Phase 36 trials
Lumos Pharma · Growth Hormone Deficiency, Growth Hormone Deficiency (GHD), Obesity & Overweight
More on obesity and weight management: recruiting trials · published research
Related in cardiovascular and metabolic: Type 2 diabetes · Type 1 diabetes · High blood pressure (hypertension) · Heart failure · High cholesterol · High triglycerides · Atrial fibrillation · Blood clots (DVT and pulmonary embolism) · Stroke prevention · Coronary artery disease and heart attack
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.